for $36 million in Series A-2 preferred stock, adding commercial-stage precision oncology platform
https://finviz.com/quote.ashx?t=ADTX&p=d
Note: Only a member of this blog may post a comment.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.